Kate Swanson1,2, Juliet C Bishop3,4, Huda B Al-Kouatly5, Mona Makhamreh5, Thomas Felton6, Neeta L Vora7, Teresa N Sparks1, Angie C Jelin3,4. 1. Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California, USA. 2. Division of Medical Genetics, Department of Pediatrics, University of California, San Francisco, California, USA. 3. Division of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. Department of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5. Division of Maternal-Fetal Medicine, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA. 6. McLendon Clinical Laboratories, Cytogenetics Laboratory, University of North Carolina Health, Chapel Hill, North Carolina, USA. 7. Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
Abstract
OBJECTIVE: There is a paucity of knowledge regarding the prenatal presentation of Klinefelter syndrome, or 47, XXY. Accurate prenatal counseling is critical and in utero diagnosis is currently limited by a poor understanding of the prenatal phenotype of this condition. METHODS: This is a case series of fetuses with cytogenetically confirmed 47, XXY in the prenatal period or up to age 5 years, with prenatal records available for review from four academic institutions between 2006 and 2019. Ultrasound reports were reviewed in detail to assess for increased nuchal translucency and structural abnormalities. Additionally, we reviewed results of cell-free DNA and serum analyte testing when performed to inform our understanding of the detection of fetal 47, XXY through standard genetic screening tests. RESULTS: Forty-one cases with confirmed cytogenetic diagnosis of 47, XXY and prenatal records available for review were identified: 37 had a prenatal diagnosis and 4 had a postnatal diagnosis. Nuchal translucency was increased ≥3.0 mm in 23.1% (6/26) of cases with a documented measurement. In 29.2% (7/24) of cases with a second trimester anatomical ultrasound available for review, a fetal abnormality was identified (3 brain anomalies, 1 cardiac abnormality, 1 echogenic bowel, and 2 limb abnormalities). Among those who had cell-free DNA and serum analytes performed, 92.6% (25/27) and 36.3% (4/11) had an abnormal result respectively. CONCLUSION: This case series expands our knowledge of the prenatal presentation of 47, XXY by identifying first and second trimester fetal sonographic abnormalities. Prenatal identification of this condition enables accurate counseling, focused prenatal management, and early postnatal interventions to ameliorate some of the known complications.
OBJECTIVE: There is a paucity of knowledge regarding the prenatal presentation of Klinefelter syndrome, or 47, XXY. Accurate prenatal counseling is critical and in utero diagnosis is currently limited by a poor understanding of the prenatal phenotype of this condition. METHODS: This is a case series of fetuses with cytogenetically confirmed 47, XXY in the prenatal period or up to age 5 years, with prenatal records available for review from four academic institutions between 2006 and 2019. Ultrasound reports were reviewed in detail to assess for increased nuchal translucency and structural abnormalities. Additionally, we reviewed results of cell-free DNA and serum analyte testing when performed to inform our understanding of the detection of fetal 47, XXY through standard genetic screening tests. RESULTS: Forty-one cases with confirmed cytogenetic diagnosis of 47, XXY and prenatal records available for review were identified: 37 had a prenatal diagnosis and 4 had a postnatal diagnosis. Nuchal translucency was increased ≥3.0 mm in 23.1% (6/26) of cases with a documented measurement. In 29.2% (7/24) of cases with a second trimester anatomical ultrasound available for review, a fetal abnormality was identified (3 brain anomalies, 1 cardiac abnormality, 1 echogenic bowel, and 2 limb abnormalities). Among those who had cell-free DNA and serum analytes performed, 92.6% (25/27) and 36.3% (4/11) had an abnormal result respectively. CONCLUSION: This case series expands our knowledge of the prenatal presentation of 47, XXY by identifying first and second trimester fetal sonographic abnormalities. Prenatal identification of this condition enables accurate counseling, focused prenatal management, and early postnatal interventions to ameliorate some of the known complications.
Authors: Michael Zitzmann; Lise Aksglaede; Giovanni Corona; Andrea M Isidori; Anders Juul; Guy T'Sjoen; Sabine Kliesch; Kathleen D'Hauwers; Jorma Toppari; Jolanta Słowikowska-Hilczer; Frank Tüttelmann; Alberto Ferlin Journal: Andrology Date: 2020-10-06 Impact factor: 3.842
Authors: Carole A Samango-Sprouse; Christine Yu; Grace F Porter; Elizabeth S Tipton; Patricia C Lasutschinkow; Andrea L Gropman Journal: Curr Opin Obstet Gynecol Date: 2020-04 Impact factor: 1.927
Authors: Olav B Petersen; Eric Smith; Diane Van Opstal; Marike Polak; Maarten F C M Knapen; Karin E M Diderich; Caterina M Bilardo; Lidia R Arends; Ida Vogel; Malgorzata I Srebniak Journal: Acta Obstet Gynecol Scand Date: 2020-05-12 Impact factor: 3.636
Authors: Carrie Guy; Farnoosh Haji-Sheikhi; Charles M Rowland; Ben Anderson; Renius Owen; Felicitas L Lacbawan; Damian P Alagia Journal: Mol Genet Genomic Med Date: 2019-01-31 Impact factor: 2.183